Revolutionizing Clinical Research: The Shift Towards Decentralized Trials

In the world of clinical research, the landscape is undergoing a significant transformation, driven by the adoption of decentralized clinical trials (DCTs). These trials leverage technology and patient-centric approaches to make the clinical research process more accessible, efficient, and patient-friendly. Even though these digital opportunities have been around for years, they have started to gain momentum only in recent years. The number of conducted DCTs has increased steadily since 2012 with and exceptional growth of 56% between 2020-2022. (GlobalData Healthcare, 2022) This trend is a testament to the growing recognition of the advantages of DCTs.

The Future Trends in Decentralized Clinical Trials

  • Remote Monitoring and Wearable Devices: With advancements in wearable technology, remote monitoring of patients has become more accessible. Wearable devices can collect continuous, real-time data, making it easier to track a patient’s health throughout a trial. This trend enhances patient compliance while enabling more real-life-like data collection.
  • Telemedicine and Virtual Visits: Telemedicine has become one of the most prominent components of DCTs. Patients can now participate in clinical trials from the comfort of their homes, reducing the burden of travel and site visits. Telemedicine not only improves patient convenience but also allows for more diverse and inclusive trial participation.
  • Decentralized Data Management: Cloud-based platforms are simplifying data collection, storage, and analysis. Decentralized data management ensures that researchers can access data securely and in real-time, increasing trial efficiency.
  • Patient-Centricity: Patient-centric design is at the core of DCTs. Trials are increasingly tailored to meet the unique needs and preferences of participants. This trend promotes patient engagement, retention, and overall satisfaction.

Challenges in Decentralized Clinical Trials

While the benefits of decentralized clinical trials are clear, realizing measurable benefits might be more challenging than expected as the industry needs to adapt its processes and systems to a new way of working. It’s important to address these challenges to ensure the success and reliability of DCTs:

  • Data Privacy and Security: As data is collected remotely, ensuring the privacy and security of patient information becomes paramount. Compliance with data protection regulations is essential.
  • Digital Divide: Not all patients have equal access to technology or the internet. Bridging the digital divide is crucial to ensure that DCTs are inclusive and representative.
  • Regulatory Hurdles: Regulatory frameworks are still evolving to accommodate DCTs. Researchers must navigate a complex landscape of regulations to conduct decentralized trials.
  • Ensuring Data Quality: Remote data collection raises concerns about data quality and integrity. Implementing robust quality control measures is essential to maintain the credibility of DCTs.


In conclusion, decentralized clinical trials are revolutionizing the field of clinical research, making trials more patient-centric, efficient, and accessible. However, it’s crucial to address the challenges associated with decentralized trials to ensure their success and reliability. As we move forward, achieving the full potential of DCTs is tightly linked to a well-functioning digital landscape. To read more about the importance of developing a digital vision that serves clinical processes, check out this whitepaper here.

Curious to know more? Read other articles here.

John Aggerholm
CEO & Project Director

John Aggerholm is the founder of the company. Before founding HERAX, John worked for 7 years for a daughter company Novo Nordisk A/S, as Vice President for eClinical Process Consulting, specializing in the improvement of clinical processes in R&D and the design and execution of Digitalization and eClinical programs. ​Before joining the Novo group, John worked 5 years as Chief Information Officer at IBM Denmark, and before that worked in IT and Clinical Operations at Henri Beaufour Institute Inc. in Washington D.C. (US).